Open AccessPhase 1 studies comparing safety, tolerability, pharmacokinetics and pharmacodynamics of HLX01 (a rituximab biosimilar) to reference rituximab in Chinese patients with CD20-positive B-cell lymphoma
Author(s) -
Yuankai Shi,
Qingyuan Zhang,
Xiaohong Han,
Yan Qin,
Xiaoyan Ke,
Hang Su,
Li Liu,
Jinxiang Fu,
Jie Jin,
Jifeng Feng,
Xin Hong,
Xiaohong Zhang,
Depei Wu,
Bin Jiang,
Xiaodong Dong
Publication year - 2021
Publication title -
chinese journal of cancer research/chinese journal of cancer research
Language(s) - English
Resource type - Journals
eISSN - 1993-0631
pISSN - 1000-9604
DOI - 10.21147/j.issn.1000-9604.2021.03.11
Subject(s) - medicine , rituximab , tolerability , pharmacodynamics , pharmacokinetics , biosimilar , adverse effect , clinical endpoint , confidence interval , pharmacology , gastroenterology , lymphoma , clinical trial
This study aimed to compare the pharmacokinetic, pharmacodynamic and safety profiles of HLX01 (a rituximab biosimilar) and reference rituximab sourced from China (MabThera ® ; rituximab-CN).